BPC-157

BPC-157 is a 7.5–8.0/10 fit for adults considering an investigational recovery peptide after basic rehab, sleep, protein, and load management are already handled, not a proven human longevity or injury cure. The cleanest evidence anchors are Vasireddi 2025, which reviewed 36 sports-medicine studies and found 35 were preclinical plus one clinical study, and Gwyer 2019, which supports the tendon, ligament, and muscle repair direction in animal work. Lee 2025 adds useful context: reported a tiny two-person IV safety pilot that cannot answer efficacy. The practical gap is the same one that shows up across the report: mechanism and early outcomes are more convincing than broad real-world certainty. In practice, BPC-157 belongs after the basics, works best when the target is specific, and deserves tracking around benefits, side effects, interactions, and cost before it becomes a standing protocol.

✅ Best for: Healthy adults with acute soft-tissue injuries, stubborn tendon or ligament recovery, muscle strains, wound-healing goals, or post-surgical recovery questions where standard care is already handled and a clinician is not concerned about angiogenesis or clotting risk. BPC-157 is most defensible as a short, scoped repair experiment layered on top of rehab, sleep, adequate protein, load management, and diagnostic clarity. Oral arginine salt is the cleaner choice for gut-focused self-experimentation, while subcutaneous acetate is the common community route for local injury protocols. Non-tested athletes and experienced peptide users should still verify product purity.

❌ Avoid if: You have current cancer, a cancer history that makes angiogenesis concerning, pre-malignant lesions, proliferative retinopathy, pregnancy, planned pregnancy, breastfeeding, therapeutic anticoagulation, unexplained pain that has not been diagnosed, or any reason sterile injection technique is unrealistic. Avoid BPC-157 if you compete under WADA rules, because BPC-157 is prohibited under S0 non-approved substances. Also avoid if you need guideline-backed medical care for ulcerative colitis, tendon rupture, neurological injury, chronic pain, or post-surgical complications. BPC-157 may be promising, but it is not standard of care.